Gold Silver Reports – Lupin Pares Losses After Signing Pact — Shares of the pharmaceutical company parred early losses and rose as much as 0.8 percent to Rs 768.
The drugmaker today entered into an agreement with CSIR-National Chemical Laboratory, Pune and Department of Science and Technology, Delhi for researching a continuous purification process development of a biosimilar monoclonal antibody therapeutic, according to its stock exchange notification.
The stock trades at 19.3 times its estimated forward earnings per share and 20.6 times for its two-year historical average, Bloomberg data showed.
